{"meta":{"query_hash":"35f83303f269","filters":{"venue":"Blood Neoplasia"},"cohort_total":18,"direct_labels_cover":0,"predictions_cover":18,"exported":18,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/35f83303f269","api":"https://metacan.xera.ac/api/v1/cohort?venue=Blood+Neoplasia"},"results":[{"id":"W4399477840","doi":"10.1016/j.bneo.2024.100022","title":"Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Johnson and Johnson; Janssen Scientific Affairs","keywords":"Ibrutinib; Hazard ratio; Medicine; Chronic lymphocytic leukemia; Internal medicine; Confidence interval; Dosing; Oncology; Adverse effect; Leukemia","score_opus":0.045808562921494676,"score_gpt":0.3896346356456451,"score_spread":0.34382607272415044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399477840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558467,0.00072602404,0.0013112453,0.00017214958,0.000035191282,0.00014195495,0.001369711,0.000027156084,0.0006318698],"genre_scores_gemma":[0.9970686,0.00009492333,0.000462908,0.000109124245,0.000027819133,0.00015905537,0.001872951,0.000014541839,0.0001901227],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9576967,0.034899995,0.0020185024,0.003086839,0.0013129961,0.000984952],"domain_scores_gemma":[0.9028769,0.068677574,0.020388719,0.005332976,0.0013846117,0.0013392819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.029114556,0.000707671,0.0015159069,0.0007908432,0.00031011252,0.0020459723,0.0015341362,0.0012216682,0.0021832765],"category_scores_gemma":[0.072245814,0.00049291854,0.0040558246,0.0014262451,0.0006339327,0.0017163246,0.0013413618,0.0018444678,0.00039378405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1385349,0.002062617,0.7873487,0.00063106965,0.016783647,0.0004978342,0.000342575,0.022559894,0.0009925297,0.00081891706,0.002423654,0.027003698],"study_design_scores_gemma":[0.012042025,0.035088055,0.7611707,0.00021380969,0.014897398,0.0014415353,0.0007518576,0.16525583,0.0021401031,0.0013449048,0.00542484,0.0002289756],"about_ca_topic_score_codex":0.0016138415,"about_ca_topic_score_gemma":0.001106565,"teacher_disagreement_score":0.029114556,"about_ca_system_score_codex":0.0010615557,"about_ca_system_score_gemma":0.0007464119,"threshold_uncertainty_score":0.15397435},"labels":[],"label_agreement":null},{"id":"W4401959513","doi":"10.1016/j.bneo.2024.100039","title":"Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Solid organ; Pathological; Organ transplantation; Transplantation; Medicine; Lymphoma; Pathology; Internal medicine","score_opus":0.010411507844044439,"score_gpt":0.28176754517615193,"score_spread":0.2713560373321075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401959513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99068004,0.0016019716,0.00038784134,0.00030740286,0.000029647388,0.000032417487,0.0002044474,0.000030884108,0.0067253537],"genre_scores_gemma":[0.9988563,0.00042721542,0.0001810493,0.00007611371,0.00004155529,0.000008919967,0.00016906901,0.0000039904585,0.00023593473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997118,0.00003669007,0.000030138724,0.00004803998,0.000055947545,0.000117332886],"domain_scores_gemma":[0.99932146,0.00016651614,0.00015032725,0.000023727902,0.00007456884,0.00026345084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028904894,0.00038782958,0.00038604205,0.0009670384,0.00047111866,0.0005438184,0.00037218927,0.0006777285,0.0014314185],"category_scores_gemma":[0.0013689304,0.00025939554,0.00037525556,0.0007692673,0.0007117887,0.00070878706,0.00040667507,0.0006725467,0.00028542566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061991403,0.0001281161,0.6148826,0.000056823257,0.000033880406,0.36621246,0.00024489342,0.00061074155,0.004816403,0.000428657,0.0011515087,0.010813962],"study_design_scores_gemma":[0.00003900163,0.0003751433,0.55205333,0.000028079445,0.00006007026,0.44297343,0.00047163066,0.0008721537,0.0013170396,0.00021667778,0.0015758398,0.00001760478],"about_ca_topic_score_codex":0.0021125004,"about_ca_topic_score_gemma":0.0021602407,"teacher_disagreement_score":0.0021125004,"about_ca_system_score_codex":0.00069339067,"about_ca_system_score_gemma":0.00061121304,"threshold_uncertainty_score":0.0050309896},"labels":[],"label_agreement":null},{"id":"W4402285270","doi":"10.1016/j.bneo.2024.100040","title":"BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"U.S. National Library of Medicine; American Cancer Society; Leukemia and Lymphoma Society; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; Musculoskeletal Research Center, Washington University in St. Louis; Genome Technology Access Center","keywords":"Downregulation and upregulation; Pathogenesis; Mutant; Cell biology; Cancer research; Chemistry; Biology; Gene; Immunology; Genetics","score_opus":0.013893049665993942,"score_gpt":0.2695817774573835,"score_spread":0.25568872779138957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402285270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98404056,0.0032761344,0.0029215373,0.0006062818,0.0001436382,0.000049885242,0.0013656107,0.00043017036,0.0071662837],"genre_scores_gemma":[0.99639904,0.00033327012,0.00082820264,0.00007097226,0.0000061924566,0.000015069707,0.0004764384,0.000014617626,0.0018561813],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9997801,0.00003682112,0.000015521346,0.00003472956,0.00006814955,0.0000646827],"domain_scores_gemma":[0.9998896,0.000018182405,0.000018104838,0.000016800941,0.000014396738,0.000042825854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019412521,0.00022401789,0.0002057732,0.0002533684,0.00026289898,0.00056264526,0.0001655061,0.000289456,0.004042124],"category_scores_gemma":[0.0001912434,0.0001108329,0.00023117008,0.00015439723,0.00023356815,0.00028374835,0.00020752681,0.0010775995,0.0005601237],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039905094,0.00010750128,0.0012054719,0.00008827436,0.000024810111,0.00007886721,0.000042602747,0.00026856345,0.989393,0.0007607375,0.0011585285,0.0064727655],"study_design_scores_gemma":[0.000044528777,0.0008309041,0.009875581,0.000012149123,0.000046763456,0.0004689912,0.00012917888,0.0016573276,0.9749337,0.00017615085,0.011816942,0.0000079393885],"about_ca_topic_score_codex":0.0026188565,"about_ca_topic_score_gemma":0.004905673,"teacher_disagreement_score":0.004042124,"about_ca_system_score_codex":0.0008496977,"about_ca_system_score_gemma":0.00043001035,"threshold_uncertainty_score":0.013522208},"labels":[],"label_agreement":null},{"id":"W4403348875","doi":"10.1016/j.bneo.2024.100045","title":"Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Irene Levi Sala Care Archaeological Foundation; Center for Individualized Medicine, Mayo Clinic; Gairdner Foundation; Mayo Clinic","keywords":"Germline; Multiple myeloma; Prospective cohort study; Oncology; Medicine; Center (category theory); Cohort; Internal medicine; Genetics; Biology; Gene","score_opus":0.00790845023562135,"score_gpt":0.25317451658200646,"score_spread":0.24526606634638512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403348875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.999273,0.0001255661,0.00005675199,0.000049492035,0.000007095693,0.0000040406953,0.00022448244,0.000004206895,0.00025523605],"genre_scores_gemma":[0.9993437,0.0000647965,0.000049287995,0.000039597446,0.000017346403,0.000005204636,0.00033752815,0.0000041224075,0.0001382527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926037,0.0001423875,0.00005772353,0.00030637518,0.00009986123,0.00013330377],"domain_scores_gemma":[0.9989329,0.00014323767,0.00042830053,0.00014554331,0.00011655652,0.00023337896],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005310354,0.0004814854,0.0005367581,0.0010027059,0.0013091754,0.0013284492,0.00067592144,0.0006992102,0.0023824945],"category_scores_gemma":[0.0022545273,0.00046033904,0.0005230423,0.0012752279,0.0005026792,0.00080236146,0.0008065427,0.00079572276,0.00038206967],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021626282,0.00004479132,0.9975847,0.0000034557743,0.00006678974,0.00038079103,0.000074564574,0.000033747412,0.0007463053,0.0000427688,0.00018068039,0.0006251413],"study_design_scores_gemma":[0.000023101453,0.00012791452,0.9956306,0.0000052229275,0.00006544129,0.0029979183,0.0004169211,0.00021763954,0.00013186765,0.000079489175,0.00029597562,0.000007837979],"about_ca_topic_score_codex":0.0030695174,"about_ca_topic_score_gemma":0.0023974036,"teacher_disagreement_score":0.0030695174,"about_ca_system_score_codex":0.00031887417,"about_ca_system_score_gemma":0.0003604548,"threshold_uncertainty_score":0.007970214},"labels":[],"label_agreement":null},{"id":"W4403707226","doi":"10.1016/j.bneo.2024.100052","title":"Pharmacological targeting of CBX7 alters the epigenetic landscape and induces differentiation of leukemic cells","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Natural Sciences and Engineering Research Council of Canada; Universitair Medisch Centrum Groningen; KWF Kankerbestrijding; AstraZeneca","keywords":"Epigenetics; Biology; Cell biology; DNA methylation; Cancer research; Epigenesis; Genetics; Gene; Gene expression","score_opus":0.008677332414844925,"score_gpt":0.24440063114828048,"score_spread":0.23572329873343556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403707226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957354,0.0007729752,0.0014689827,0.00009061284,0.000023414177,0.00002903885,0.00022836076,0.000087477994,0.0015637798],"genre_scores_gemma":[0.9965953,0.00047280738,0.00083807315,0.00004022463,0.0000044252306,0.000027176055,0.00024090214,0.000014291496,0.0017668777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998785,0.000018091088,0.000011682656,0.000023567003,0.00003476503,0.000033368287],"domain_scores_gemma":[0.9999391,0.000013088428,0.000013224361,0.000006641292,0.0000051900865,0.000022748281],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012105148,0.0002773056,0.0002842517,0.0002523202,0.00012152289,0.00024725244,0.00021949183,0.00021539563,0.0012382003],"category_scores_gemma":[0.00007981415,0.000099750185,0.0001467606,0.00015242887,0.00028513736,0.00013068866,0.00015552242,0.00058555335,0.00023122343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009203073,0.000056819405,0.00008006344,0.00001712274,0.000004153955,0.000026634834,0.0000073853303,0.00008192473,0.9985366,0.00015157623,0.000028910628,0.0009167429],"study_design_scores_gemma":[0.000017529946,0.00023970343,0.0008231351,0.0000022290333,0.000009246172,0.000052786832,0.000012893514,0.0007455575,0.9972783,0.000031817643,0.0007851811,0.0000016344794],"about_ca_topic_score_codex":0.0007148045,"about_ca_topic_score_gemma":0.0014066624,"teacher_disagreement_score":0.0012382003,"about_ca_system_score_codex":0.0003251716,"about_ca_system_score_gemma":0.0002644405,"threshold_uncertainty_score":0.004142165},"labels":[],"label_agreement":null},{"id":"W4403707232","doi":"10.1016/j.bneo.2024.100050","title":"Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"University of Calgary","keywords":"Multiple myeloma; In vivo; In vitro; Pharmacology; Medicine; Chemistry; Biology; Internal medicine; Biochemistry; Biotechnology","score_opus":0.0566284165187802,"score_gpt":0.36746191264710704,"score_spread":0.31083349612832684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403707232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9437236,0.03529928,0.006434742,0.0009412234,0.00027534633,0.0012857645,0.002857261,0.00049250334,0.008690254],"genre_scores_gemma":[0.95907587,0.024672939,0.005031026,0.00031361225,0.00009737377,0.00051326497,0.004075104,0.00007805846,0.0061427723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99977285,0.00005174756,0.000011903742,0.000041170795,0.000056218287,0.000066044144],"domain_scores_gemma":[0.99980706,0.000027156671,0.000042007683,0.000019341813,0.000031292926,0.00007312337],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082069775,0.0011012255,0.0010535873,0.00091843156,0.0004440945,0.000601811,0.0007242209,0.0005260259,0.0020894513],"category_scores_gemma":[0.00027195463,0.00037998543,0.0005507368,0.00071663584,0.00037048088,0.00048462843,0.0002564804,0.0016978653,0.0004600622],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007078252,0.012038347,0.0016244765,0.0006389337,0.00028465933,0.00028513372,0.00012657017,0.003811205,0.90514404,0.00040100355,0.0025361564,0.0660312],"study_design_scores_gemma":[0.004824603,0.090823226,0.0124695,0.00009371093,0.0007404877,0.001076189,0.00009074964,0.004890497,0.85376716,0.0002827359,0.030882012,0.000059052592],"about_ca_topic_score_codex":0.004409211,"about_ca_topic_score_gemma":0.0082816295,"teacher_disagreement_score":0.004409211,"about_ca_system_score_codex":0.0010247579,"about_ca_system_score_gemma":0.0010630342,"threshold_uncertainty_score":0.008767128},"labels":[],"label_agreement":null},{"id":"W4406732078","doi":"10.1016/j.bneo.2025.100070","title":"Race and age disparities in randomized trials of acute myeloid leukemia: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Blood Neoplasia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Toronto; York University; McMaster University","funders":"","keywords":"Myeloid leukemia; Meta-analysis; Race (biology); Medicine; Randomized controlled trial; Oncology; Internal medicine; Sociology; Gender studies","score_opus":0.07367181825528708,"score_gpt":0.38412831072266646,"score_spread":0.3104564924673794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406732078","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034330715,0.99475515,0.00042441784,0.00024228754,0.000121161975,0.00034812168,0.00041349107,0.000018953499,0.00024333772],"genre_scores_gemma":[0.14275852,0.84903324,0.003171377,0.0014141257,0.00034437265,0.002090602,0.0008535417,0.000037919035,0.00029626422],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.96815914,0.01706859,0.009491357,0.0019815266,0.0027007458,0.00059854414],"domain_scores_gemma":[0.91180414,0.07239437,0.0105613675,0.001541354,0.0032301096,0.00046866274],"candidate_categories":["metaresearch","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.031401627,0.0022401006,0.020465333,0.006907232,0.00075233233,0.0037778297,0.0021096908,0.0021979453,0.0037577443],"category_scores_gemma":[0.084407955,0.0013900099,0.028374786,0.00898782,0.0009903263,0.002438473,0.0016924646,0.0018883286,0.00028359526],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015686888,0.000021467795,0.0042764735,0.55177927,0.4279893,0.0001016017,0.00011058439,0.00042679664,0.00014335598,0.00023949047,0.00079004985,0.012552871],"study_design_scores_gemma":[0.00093269016,0.0002075195,0.0047912775,0.07281097,0.91800743,0.00010598392,0.00006814858,0.0002322998,0.00012693509,0.0003824901,0.0023095233,0.000024676792],"about_ca_topic_score_codex":0.005650781,"about_ca_topic_score_gemma":0.012970601,"teacher_disagreement_score":0.9795347,"about_ca_system_score_codex":0.0036139078,"about_ca_system_score_gemma":0.005006687,"threshold_uncertainty_score":0.16606963},"labels":[],"label_agreement":null},{"id":"W4410267430","doi":"10.1016/j.bneo.2025.100115","title":"Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Menarini Group","keywords":"Chronic myelomonocytic leukemia; Medicine; Interleukin-3 receptor; Leukemia; Oncology; Phase (matter); Internal medicine; Cancer research; Chemistry; Myelodysplastic syndromes; Bone marrow","score_opus":0.03274721435044482,"score_gpt":0.349430216785658,"score_spread":0.3166830024352132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410267430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98576003,0.008571262,0.0010030132,0.0006317189,0.00009032298,0.0011049086,0.0011668175,0.00009936883,0.001572478],"genre_scores_gemma":[0.9816144,0.0070329993,0.001974625,0.0013199223,0.00016892666,0.001384597,0.00429509,0.000054531574,0.0021548998],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996302,0.00018960962,0.000015750904,0.00004258418,0.000044107488,0.000077786324],"domain_scores_gemma":[0.99951816,0.00009963146,0.00008285528,0.00004153063,0.00004908606,0.00020881528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023057812,0.0011325879,0.001251529,0.00026105664,0.00023298165,0.0007814253,0.00055088144,0.0010053014,0.0012701821],"category_scores_gemma":[0.0007580709,0.00026096305,0.0008934792,0.00026198893,0.00043096195,0.00045820326,0.00018317242,0.0014548074,0.00039329467],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31928945,0.06699803,0.017191658,0.001964016,0.002848856,0.0012135601,0.0008338243,0.007421971,0.15688846,0.00075920636,0.014846001,0.409745],"study_design_scores_gemma":[0.29127747,0.62756807,0.045200463,0.00015497877,0.0015237246,0.001322375,0.00010994577,0.003170492,0.015228015,0.00047921966,0.013899974,0.00006531109],"about_ca_topic_score_codex":0.00088079885,"about_ca_topic_score_gemma":0.0015430048,"teacher_disagreement_score":0.0023057812,"about_ca_system_score_codex":0.0005530938,"about_ca_system_score_gemma":0.000818162,"threshold_uncertainty_score":0.012194276},"labels":[],"label_agreement":null},{"id":"W4410267432","doi":"10.1016/j.bneo.2025.100110","title":"Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Roche","keywords":"Myeloid leukemia; Refractory (planetary science); Medicine; Antibody; Bispecific antibody; Leukemia; Immunology; Oncology; Cancer research; Monoclonal antibody; Biology","score_opus":0.015639571765158587,"score_gpt":0.3125268000374506,"score_spread":0.296887228272292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410267432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99828464,0.00047821578,0.00034358355,0.000055311557,0.000017503044,0.00028233748,0.00011231155,0.00004178095,0.00038421998],"genre_scores_gemma":[0.9973744,0.00043376256,0.0007604081,0.000110309804,0.000029749228,0.00030688642,0.0003621743,0.00001336618,0.0006088462],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99955434,0.00023315274,0.000025702151,0.000057536086,0.000051319144,0.00007784551],"domain_scores_gemma":[0.9997508,0.00004292597,0.000057990947,0.000034929366,0.00001723497,0.00009604106],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008661655,0.0008393591,0.0013378443,0.00044590904,0.00020826302,0.00045851042,0.0006362964,0.0004850696,0.0010064499],"category_scores_gemma":[0.0004156899,0.0003219748,0.00044982112,0.00033387222,0.0004584621,0.00034100428,0.00026507128,0.0016120048,0.00034765524],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15808108,0.08794211,0.00791683,0.00063413446,0.00069957314,0.0005461412,0.0006326558,0.008726038,0.5627411,0.00047275712,0.0022375882,0.16936998],"study_design_scores_gemma":[0.10456989,0.8157237,0.022233872,0.000032319567,0.0003904052,0.00058465754,0.00008768964,0.0047717104,0.047722727,0.00021569476,0.0036249075,0.000042457024],"about_ca_topic_score_codex":0.00070171186,"about_ca_topic_score_gemma":0.0015183209,"teacher_disagreement_score":0.0013378443,"about_ca_system_score_codex":0.000583276,"about_ca_system_score_gemma":0.0006116918,"threshold_uncertainty_score":0.004580736},"labels":[],"label_agreement":null},{"id":"W4410488748","doi":"10.1016/j.bneo.2025.100117","title":"Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"Institut canadien d'information sur la santé; Princess Margaret Cancer Foundation; Ministry of Long-Term Care; Institute for Clinical Evaluative Sciences; Ministry of Health, Uganda; Ontario Ministry of Health and Long-Term Care","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Population; Survival analysis; Medicine; Oncology; Internal medicine; Environmental health","score_opus":0.004499670534224287,"score_gpt":0.2224345223380903,"score_spread":0.21793485180386601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410488748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984042,0.00018299824,0.00005236781,0.000041571984,0.0000028032484,0.0000059617223,0.0010891025,0.000002718251,0.00021813034],"genre_scores_gemma":[0.9989831,0.000054770397,0.000026914016,0.00001808744,0.0000047962794,0.000004208214,0.0008579048,0.0000011867708,0.000049044953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999485,0.00009489782,0.000040632935,0.00013766567,0.000110843575,0.0001309013],"domain_scores_gemma":[0.9990396,0.00012676463,0.00036061704,0.0000986143,0.00016677442,0.00020770363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00061700214,0.00026365576,0.000352274,0.0007628109,0.0006092132,0.00078998646,0.0005061911,0.00043523725,0.0009844674],"category_scores_gemma":[0.0013236557,0.00021207392,0.00061354646,0.0019622534,0.00046913142,0.00034989428,0.00054468703,0.0005484327,0.00013735595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041637402,0.000006878868,0.9995042,0.0000024925064,0.00004737352,0.000016115107,0.000020323514,0.000028019125,0.000048500096,0.0000053900503,0.00006327288,0.00021578213],"study_design_scores_gemma":[0.000004460368,0.00002034964,0.9994956,0.0000019119077,0.000022056633,0.000039166716,0.00010484217,0.00015770961,0.000010422512,0.000008657855,0.00013248084,0.000002240736],"about_ca_topic_score_codex":0.1846601,"about_ca_topic_score_gemma":0.21490128,"teacher_disagreement_score":0.1846601,"about_ca_system_score_codex":0.001846692,"about_ca_system_score_gemma":0.0014186099,"threshold_uncertainty_score":0.3671705},"labels":[],"label_agreement":null},{"id":"W4410488951","doi":"10.1016/j.bneo.2025.100118","title":"Replication of a GWAS signal near HLA-DQA2 with AML using a disease-only cohort and external population-based controls","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"T-cell and B-cell Immunology","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Centre Hospitalier Universitaire Sainte-Justine; Hôpital Maisonneuve-Rosemont; Université de Montréal; Montreal Heart Institute","funders":"Fondation Charles-Bruneau; Fondation Institut de Cardiologie de Montréal; Centre hospitalier universitaire Sainte-Justine; Canada Research Chairs; Fonds de Recherche du Québec - Santé; Cole Foundation; Ministère de l'Économie, de l’Innovation et des Exportations du Québec; Génome Québec; Canadian Institutes of Health Research; Alliance de recherche numérique du Canada; Genome Canada","keywords":"Replication (statistics); Human leukocyte antigen; Cohort; Genome-wide association study; Population; Disease; Medicine; Biology; Immunology; Genetics; Virology; Internal medicine; Environmental health; Gene; Single-nucleotide polymorphism; Antigen","score_opus":0.006584351798126484,"score_gpt":0.22483287557123646,"score_spread":0.21824852377311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410488951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899548,0.00028242765,0.0064396174,0.00014672863,0.00008140667,0.0001147589,0.002042646,0.000075978925,0.0008615767],"genre_scores_gemma":[0.99637383,0.000045935118,0.0015756759,0.0000950837,0.0000253509,0.00009139228,0.0014304047,0.000039779017,0.00032245644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99295443,0.002902531,0.00047920592,0.0025514748,0.00077210163,0.00034032934],"domain_scores_gemma":[0.993002,0.0016460913,0.0007198833,0.0035610616,0.00071220176,0.00035879237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009406337,0.0010741733,0.00078700646,0.0008888537,0.0015330892,0.0012525915,0.0009964567,0.00085799186,0.0026387777],"category_scores_gemma":[0.011656575,0.0004322275,0.0018044113,0.0012548185,0.00076939113,0.00032327647,0.0011385065,0.0009848741,0.0004428698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032321601,0.00029843103,0.9111717,0.00013524981,0.0051030116,0.0019232879,0.0012614962,0.0008681513,0.06326629,0.00072786945,0.0018387529,0.010173571],"study_design_scores_gemma":[0.0009210241,0.0008999066,0.9804622,0.0000363007,0.0023130663,0.0016934056,0.00035842252,0.001585572,0.006269262,0.0005069889,0.004913839,0.00003998553],"about_ca_topic_score_codex":0.0106157875,"about_ca_topic_score_gemma":0.00908466,"teacher_disagreement_score":0.0106157875,"about_ca_system_score_codex":0.0004344644,"about_ca_system_score_gemma":0.00054658245,"threshold_uncertainty_score":0.049746096},"labels":[],"label_agreement":null},{"id":"W4411923937","doi":"10.1016/j.bneo.2025.100132","title":"Posttranscriptional activity of eIF4E contributes to HoxA9-driven leukemogenesis","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Canada Research Chairs","keywords":"EIF4E; Biology; Genetics; Translation (biology); Gene; Messenger RNA","score_opus":0.005928059311746098,"score_gpt":0.22752285592108457,"score_spread":0.22159479660933848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411923937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985336,0.0030758025,0.006429944,0.00034761272,0.00017053742,0.000027399989,0.00061595184,0.00021569608,0.0037809769],"genre_scores_gemma":[0.9947877,0.0004030573,0.001600989,0.0000466015,0.000021635304,0.000010683402,0.00042739173,0.000027548536,0.0026745568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998574,0.000021755106,0.0000123465825,0.00003550917,0.00002761088,0.000045252113],"domain_scores_gemma":[0.99986124,0.000025279433,0.000037408285,0.000021146427,0.000017831055,0.00003702878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019216062,0.0002996672,0.00019608652,0.00029773838,0.00032837602,0.0004947508,0.00017945473,0.00030379603,0.0025381807],"category_scores_gemma":[0.00017906552,0.0001506283,0.00027145026,0.00011409464,0.0002618059,0.00015733812,0.00036669755,0.00062860845,0.0006724496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021373066,0.000026973328,0.0009463487,0.000031624433,0.000006352936,0.00021473216,0.000010002152,0.00008428076,0.99546164,0.00049958326,0.00013400956,0.0023706474],"study_design_scores_gemma":[0.000026360925,0.000113118105,0.03108054,0.000012783419,0.000017533019,0.00063123566,0.0000647599,0.0015589471,0.959676,0.0002898183,0.0065224636,0.0000064690726],"about_ca_topic_score_codex":0.0002927478,"about_ca_topic_score_gemma":0.0005065307,"teacher_disagreement_score":0.0025381807,"about_ca_system_score_codex":0.0003532131,"about_ca_system_score_gemma":0.00021502936,"threshold_uncertainty_score":0.008491039},"labels":[],"label_agreement":null},{"id":"W4412907802","doi":"10.1016/j.bneo.2025.100148","title":"Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Alberta Children's Hospital Foundation","keywords":"Growth inhibition; Leukemia; Cancer research; Chemistry; Biology; Genetics; Cell growth","score_opus":0.005888901129144163,"score_gpt":0.24525592257876533,"score_spread":0.23936702144962116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412907802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98506445,0.005660361,0.0008134961,0.00021005387,0.000059900525,0.0001201267,0.0007706358,0.00017874774,0.0071223034],"genre_scores_gemma":[0.9925235,0.0029102038,0.0006407198,0.000087279346,0.000012808164,0.00004724849,0.0009640985,0.000016766506,0.0027973817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999491,0.000008258631,0.000003975745,0.000007016004,0.000011516,0.000020117961],"domain_scores_gemma":[0.9999672,0.000005179354,0.0000056706253,0.0000036510253,0.000003950245,0.000014260479],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000110013905,0.00037725776,0.00029644734,0.00020896296,0.000098567216,0.00027670187,0.00022506241,0.00014456983,0.001721518],"category_scores_gemma":[0.000079906524,0.000076773584,0.00019173985,0.00015876818,0.00011480565,0.000091803464,0.00011507748,0.00046759404,0.0003496717],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022256086,0.0007562811,0.0017422672,0.00021847144,0.000044827833,0.00025099548,0.000037314836,0.0009412102,0.957017,0.0003274018,0.001319552,0.03511908],"study_design_scores_gemma":[0.0006487206,0.0062201465,0.019753063,0.00002675708,0.0000866265,0.0010923628,0.000055788038,0.0025723693,0.9503289,0.00007457715,0.019126015,0.000014743288],"about_ca_topic_score_codex":0.001643038,"about_ca_topic_score_gemma":0.0058607273,"teacher_disagreement_score":0.001721518,"about_ca_system_score_codex":0.00048542483,"about_ca_system_score_gemma":0.00039707017,"threshold_uncertainty_score":0.00575912},"labels":[],"label_agreement":null},{"id":"W4413605538","doi":"10.1016/j.bneo.2025.100165","title":"Final safety and efficacy results from a phase 1/2 study of tagraxofusp, a CD123-targeted therapy, for myelofibrosis","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Princess Margaret Cancer Centre","funders":"Menarini Group","keywords":"Myelofibrosis; Medicine; Phase (matter); Targeted therapy; Oncology; Internal medicine; Chemistry; Bone marrow; Cancer","score_opus":0.026818573508397035,"score_gpt":0.31592032229977934,"score_spread":0.2891017487913823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413605538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99131596,0.0016166166,0.0013496964,0.00039785056,0.00005305711,0.001717108,0.0018824852,0.00009465093,0.0015725902],"genre_scores_gemma":[0.98933965,0.0010143499,0.0018147026,0.0006289863,0.00010332082,0.0013347279,0.0044425293,0.000035893503,0.0012858673],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9994836,0.00029500935,0.00003132974,0.00006485589,0.000051535077,0.00007357663],"domain_scores_gemma":[0.9991947,0.0002215117,0.00012879254,0.00008781037,0.00008578647,0.00028147217],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019865686,0.0009538003,0.0012170689,0.000250307,0.00037623724,0.00054997933,0.00047287694,0.00084885367,0.0017971916],"category_scores_gemma":[0.0012708234,0.00030997625,0.000880196,0.00019511297,0.0005370163,0.0004555725,0.00019198845,0.0019027131,0.00040052691],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4763322,0.06541855,0.017986339,0.0010650536,0.001653044,0.0015512555,0.00066130835,0.0070292903,0.23535152,0.0004648918,0.011426488,0.18106006],"study_design_scores_gemma":[0.22064905,0.7137631,0.03127469,0.00005369121,0.0009658829,0.001204836,0.00006923611,0.0022065362,0.02322168,0.00038743997,0.0061561116,0.000047761732],"about_ca_topic_score_codex":0.0005329964,"about_ca_topic_score_gemma":0.0009842878,"teacher_disagreement_score":0.0019865686,"about_ca_system_score_codex":0.0004448438,"about_ca_system_score_gemma":0.0008317211,"threshold_uncertainty_score":0.0105060935},"labels":[],"label_agreement":null},{"id":"W4413885244","doi":"10.1016/j.bneo.2025.100164","title":"Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"CD19; Refractory (planetary science); Lymphoma; Oncology; Medicine; Internal medicine; CAR T-cell therapy; Cancer research; Chimeric antigen receptor; Biology; Immunotherapy; Cancer","score_opus":0.025083253545016972,"score_gpt":0.320445708459025,"score_spread":0.29536245491400803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413885244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986021,0.0010293322,0.000043894568,0.000038707243,0.0000046024566,0.0000040273103,0.000049183174,0.0000022061693,0.00022589914],"genre_scores_gemma":[0.99957126,0.00018532548,0.00001496563,0.000037681148,0.000007784849,0.0000030852766,0.00012802304,9.299831e-7,0.000050980067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99985087,0.000050062834,0.000016401396,0.000024565661,0.000020868418,0.000037126592],"domain_scores_gemma":[0.99931014,0.00020711988,0.00025793578,0.000025486108,0.000032815315,0.00016656666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034747433,0.00008132196,0.00029146118,0.0002450805,0.00014414176,0.00040540486,0.00009739019,0.00023275116,0.0008708253],"category_scores_gemma":[0.0010495831,0.000047766705,0.00039415364,0.00027300496,0.0001753233,0.00022990708,0.00023401286,0.0002651724,0.00013606735],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009001714,0.000206294,0.925958,0.00014190676,0.00023616132,0.0011859637,0.00035350496,0.00041449306,0.004423425,0.000102903374,0.00052330986,0.057452306],"study_design_scores_gemma":[0.0002251052,0.003761134,0.9904919,0.000049422368,0.00022912573,0.0026147163,0.0003138792,0.00041670093,0.00061237864,0.00018830248,0.001088655,0.000008685662],"about_ca_topic_score_codex":0.0004033433,"about_ca_topic_score_gemma":0.000731341,"teacher_disagreement_score":0.0008708253,"about_ca_system_score_codex":0.00024089582,"about_ca_system_score_gemma":0.00015148126,"threshold_uncertainty_score":0.002913177},"labels":[],"label_agreement":null},{"id":"W4415973831","doi":"10.1016/j.bneo.2025.100182","title":"Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Servier","keywords":"Somatic evolution in cancer; Myeloid leukemia; Isocitrate dehydrogenase; Drug resistance; Leukemia; Myeloid","score_opus":0.01181312530648026,"score_gpt":0.24337750170542444,"score_spread":0.23156437639894417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415973831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97846025,0.000505107,0.01890683,0.000085509484,0.0000180951,0.00008309168,0.00094147405,0.00014733178,0.0008523284],"genre_scores_gemma":[0.98298395,0.00046002484,0.013411152,0.000057925346,0.0000066617226,0.000108749744,0.001209488,0.0000442093,0.0017178451],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99988735,0.000015785185,0.000009224363,0.000027227732,0.000044201548,0.000016272661],"domain_scores_gemma":[0.99986744,0.000025160918,0.000040751805,0.000017448749,0.000019400768,0.000029734329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019260691,0.00022454734,0.00020496937,0.00036809104,0.00015066333,0.0002967751,0.00016635652,0.00024195631,0.0005841959],"category_scores_gemma":[0.00015204896,0.00010930765,0.00015322774,0.0001651155,0.00017737098,0.00017880226,0.00023559295,0.00044969507,0.00012830722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067587964,0.000028633667,0.00097608403,0.000011011914,0.0000080817435,0.000034586723,0.000016447668,0.00038899822,0.996811,0.00012719807,0.000047096604,0.0014832888],"study_design_scores_gemma":[0.000017581782,0.00042515626,0.02134459,0.0000047404287,0.000034780438,0.00054670963,0.00005203833,0.015600806,0.95914364,0.00022992269,0.0025900109,0.000009971416],"about_ca_topic_score_codex":0.00050139695,"about_ca_topic_score_gemma":0.00092969846,"teacher_disagreement_score":0.0005841959,"about_ca_system_score_codex":0.00025888954,"about_ca_system_score_gemma":0.00009931094,"threshold_uncertainty_score":0.001954317},"labels":[],"label_agreement":null},{"id":"W4416028285","doi":"10.1016/j.bneo.2025.100179","title":"Mezigdomide combined with bortezomib disrupts the cell cycle and elicits superior antitumor effects in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Bortezomib; Multiple myeloma; Proteasome; In vivo; Proteasome inhibitor; Cereblon; Cytotoxic T cell; Pomalidomide; Cell cycle","score_opus":0.0024778140326348914,"score_gpt":0.19639746734811725,"score_spread":0.19391965331548236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416028285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966085,0.0018275214,0.00044827576,0.000047597037,0.00003610936,0.00003345987,0.0001580619,0.000039503684,0.00080092443],"genre_scores_gemma":[0.99699116,0.000998984,0.0007345348,0.000036356785,0.000021831189,0.000028935725,0.0003132058,0.000009643149,0.00086524634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99987483,0.000021300988,0.00001141904,0.000025469886,0.00003016581,0.000036788384],"domain_scores_gemma":[0.9999409,0.000009306025,0.000011729178,0.000007354332,0.0000043516743,0.000026414324],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013620767,0.00027768657,0.0005736426,0.00032269082,0.00012522892,0.00025891498,0.0002216331,0.00022305813,0.0010238932],"category_scores_gemma":[0.0001187189,0.00011855893,0.00023086347,0.0002602534,0.00014613487,0.00020986088,0.00020988609,0.00073235645,0.00022689514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003081377,0.0007586944,0.0004674729,0.000081694816,0.00003235485,0.00007056187,0.000031722542,0.00063740683,0.9802688,0.00010568587,0.00023658438,0.014227625],"study_design_scores_gemma":[0.0006107422,0.018208943,0.008769799,0.000011480534,0.000086761545,0.00043225268,0.0000350101,0.0017884888,0.96550924,0.000084471794,0.004448096,0.000014637241],"about_ca_topic_score_codex":0.00073278055,"about_ca_topic_score_gemma":0.0013752163,"teacher_disagreement_score":0.0010238932,"about_ca_system_score_codex":0.00023236447,"about_ca_system_score_gemma":0.00025731022,"threshold_uncertainty_score":0.0034252405},"labels":[],"label_agreement":null},{"id":"W4416386731","doi":"10.1016/j.bneo.2025.100184","title":"Outcomes of transplant-eligible and transplant-ineligible patients with mantle cell lymphoma in Ontario","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Medical Council of Canada; Institute for Clinical Evaluative Sciences","keywords":"Mantle cell lymphoma; Chemoimmunotherapy; Rituximab; Retrospective cohort study; Lymphoma; Overall survival","score_opus":0.004504251309844768,"score_gpt":0.20126007053874237,"score_spread":0.1967558192288976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416386731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986902,0.00013768759,0.000020210826,0.0000774057,0.0000020848438,0.000011348625,0.00059688557,0.000001883934,0.00046226656],"genre_scores_gemma":[0.999186,0.00010404642,0.000021326992,0.00005673882,0.000004108061,0.0000066394873,0.00047206995,0.0000012128546,0.00014795964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99951863,0.000044590317,0.000054273678,0.00008747269,0.00011276407,0.0001824124],"domain_scores_gemma":[0.9986808,0.00006985504,0.0006483029,0.000046875295,0.00019357694,0.00036051814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029767113,0.00016691438,0.0002853843,0.0005910038,0.0010659492,0.00081312674,0.0006215809,0.00027595102,0.00096510095],"category_scores_gemma":[0.0012394075,0.0002131457,0.0003148342,0.0016481511,0.0005992145,0.00039755728,0.0008164949,0.00031710646,0.00013602739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006695143,0.000018701174,0.99823785,0.000009100067,0.000011018636,0.00012777447,0.0002459392,0.00003862197,0.00016117032,0.000018221279,0.00011051233,0.00095395267],"study_design_scores_gemma":[0.000011130814,0.000051435432,0.99893147,0.0000068927507,0.000010497957,0.00015001399,0.00042193165,0.000082558814,0.00003680162,0.000015806987,0.00027768846,0.0000037320196],"about_ca_topic_score_codex":0.6136837,"about_ca_topic_score_gemma":0.7658387,"teacher_disagreement_score":0.3863163,"about_ca_system_score_codex":0.00950383,"about_ca_system_score_gemma":0.00497954,"threshold_uncertainty_score":0.77718276},"labels":[],"label_agreement":null}]}